April 01, 2026
Phapros Records Net Profit Growth of Up to 109% in 2025, Driven by Significant Sales Increase & Production Cost Efficiency
The issuer with the stock code PEHA successfully recorded a net profit of Rp27.44 billion from January to December 2025, an increase of 109% compared to the same period the previous year, which still recorded a loss of Rp290.63 billion. ...
See More
March 19, 2026
Phapros Accompanies Homebound Travelers,Strengthens Role as the Community's "Sahabat Sehat"
PT Phapros Tbk (PEHA) reaffirms its commitment to supporting public health through the "Phapros Sahabat Sehat" ...
See More
December 20, 2025
Phapros Introduces New Product for Adult Men's Health at INASAU 2025
PT Phapros Tbk (PEHA) reaffirms its commitment to supporting the improvement of men's health quality through its participation and support at The 4th InaSAU Meeting...
See More
December 12, 2025
Phapros Supports Hydrocephalus Surgery in Tobelo, North Maluku
PT Phapros Tbk (PEHA) once again demonstrated its commitment to supporting the improvement of public health in the eastern region of Indonesia by participating in the "Governor's Christmas Gift in the Month of Love" event....
See More
December 01, 2025
Phapros Records Over 2000% YoY EBITDA Surge and Double-Digit Sales Growth in Q3 2025
PT Phapros Tbk (PEHA), successfully recorded positive performance up to the third quarter of 2025....
See More
November 18, 2025
Phapros Amplifies the Importance of Holistic Health Through Support for the Film "Menuju Pelaminan"
The film, which depicts social conditions and the challenges of cultural differences set against the backdrop of various journeys by land, sea, and air, is highly relevant to Antimo's positioning as a motion sickness medication with the tagline "Family Travel Companion."...
See More